Wyeth Prempro DTC
Executive Summary
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...
You may also be interested in...
Prempro Low(er) Clears FDA: .3 mg/1.5 mg Is Start Dose For Osteoporosis
Wyeth's Prempro osteoporosis prevention treatment should begin with .3 mg conjugated estrogens/1.5 mg medroxyprogesterone following FDA approval of the lowest dose of the hormone therapy June 4
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Wyeth's approval of lower-dose Prempro gives the company a positive marketing message to counter the safety concerns raised by the Women's Health Initiative hormone replacement therapy study findings
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.